dnPD-1(MUC-1+CD 19)CAR-T细胞治疗复发或转移性乳腺癌的临床研究  

Clinical study of dnPD-1(MUC-1+CD 19)CAR T cells in treatment of recurrent or metastatic breast cancer

作　　者：宋海侠[1] 岳晓华 张小平[2] 祁海燕[1] 孙少伯[2] 王碧莹 耿广琴[2] SONG Haixia;YUE Xiaohua;ZHANG Xiaoping;QI Haiyan;SUN Shaobo;WANG Biying;GENG Guangqin(Cancer Hospital of Gansu Province,Lanzhou,Gansu 730050,China;Gansu University of Chinese Medicine,Lanzhou,Gansu 730000,China)

机构地区：[1]甘肃省肿瘤医院,甘肃兰州730050 [2]甘肃中医药大学,甘肃兰州730000

出　　处：《中国医学工程》2021年第10期1-5,共5页China Medical Engineering

基　　金：国家自然科学基金资助课题(81360345);甘肃省卫生行业科研计划项目(GSWSKY-2019-86);甘肃省中医药管理局科研课题(GZK-2018-40);甘肃省卫生行业科研计划项目(GSWSKY-2018-75)。

摘　　要：目的评价dnPD-1[粘蛋白1(MUC-1)+CD19]CAR-T细胞临床治疗复发或转移性乳腺癌的安全性和有效性。方法取患者外周血进行T细胞分离、纯化、激活后,使用病毒载体导入MUC-1的嵌合抗原受体(CAR)基因,获得生产靶向MUC-1 CAR-T的T细胞并扩增,静脉回输注患者体内进行治疗。期间检测患者细胞因子、PET-CT检查变化等并进行疗效评估。结果dnPD-1(MUC-1+CD19)CAR-T细胞治疗使患者的疾病缓解持续时间和无进展生存期可达6个月,整体安全性较好。结论dnPD-1(MUC-1+CD19)CAR-T细胞治疗对复发或转移性乳腺癌有较好的控制,安全性和稳定性良好。【Objective】To evaluate the safety and efficacy of dnPD-1(MUC-1+CD 19)CAR T cells in the treatment of recurrent or metastatic breast cancer.【Methods】After the peripheral blood T cells were isolated,purified and activated,the MUC-1 CAR gene was introduced by virus vector to obtain and amplify the CAR-T cells targeting MUC-1.The T cells were reinjected into the patients for treatment.The changes of cytokines and PET-CT were detected and the curative effect was evaluated.【Results】The duration of remission and progression free survival of patients with(MUC-1+CD 19)CAR T cell therapy can reach 6 months,and the overall safety is desirable.【Conclusion】dnPD-1(MUC-1+CD 19)CAR T cell therapy is safe and stable in the treatment of recurrent or metastatic breast cancer.

关 键 词：乳腺癌 CAR-T细胞治疗 粘蛋白1基因 研究 

分 类 号：R737.9[医药卫生—肿瘤]